Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

BACKGROUND: Alemtuzumab is a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS), and immune thrombocytopenia (ITP) has been identified as a risk. OBJECTIVE: To examine ITP incidence, treatment, and outcomes during the clinical development of alemtuzumab for RRMS and discuss p...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mult Scler
Autori principali: Cuker, Adam, Bass, Ann D, Nadj, Congor, Agius, Mark A, Steingo, Brian, Selmaj, Krzysztof W, Thoits, Timothy, Guerreiro, Alexandre, Van Wijmeersch, Bart, Ziemssen, Tjalf, Meuth, Sven G, LaGanke, Christopher C, Thangavelu, Karthinathan, Rodriguez, Claudio E, Baker, Darren P, Margolin, David H, Jannsens, Ann
Natura: Artigo
Lingua:Inglês
Pubblicazione: SAGE Publications 2019
Soggetti:
Original Research Papers
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6950888/
https://ncbi.nlm.nih.gov/pubmed/30785358
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458518816612
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi